DGX

Quest Diagnostics
D

DGX

Arincen63/100B
255.59
USD
0.87
(0.34%)
Pre Open
Fair value202.30Plus+26%77Price 255.59264
Q4 FY2026 · Earnings report
EPS estimate 2.68Revenue estimate 3.04B
OverviewFinancialsForecastEarningsDividendsCompany

Quest Diagnostics net income 1996–2026

Quest Diagnostics earned 312.00M USD in Q3 FY2026, the three months to 30 September 2026, up 27.3% on the same quarter a year before. Quest Diagnostics's net income over the last twelve months was 1.13B USD, up 16.5% on the twelve months before. In fiscal year 2025 it earned 992.00M USD, up 13.9% on the year before.

Last updated 7 Nov 2026 · Next report 9 Feb 2027

Net income

Net income · +3.4% a year over 10 yearsNet margin

Growth

Fiscal yearPeriod endingNet incomeGrowthNet marginRevenue
TTM30 Sept 20261.13B+16.51%9.53%11.84B
FY202531 Dec 2025992.00M+13.89%8.99%11.04B
FY202431 Dec 2024871.00M+1.99%8.82%9.87B
FY202331 Dec 2023854.00M-9.73%9.23%9.25B
FY202231 Dec 2022946.00M-52.58%9.57%9.88B
FY202131 Dec 20212.00B+39.41%18.49%10.79B
FY202031 Dec 20201.43B+66.78%15.16%9.44B
FY201931 Dec 2019858.00M+16.58%11.11%7.73B
FY201831 Dec 2018736.00M-4.66%9.77%7.53B
FY201731 Dec 2017772.00M+19.69%10.01%7.71B
FY201631 Dec 2016645.00M-9.03%8.58%7.52B
FY201531 Dec 2015709.00M+27.52%9.46%7.49B
FY201431 Dec 2014556.00M-34.51%7.48%7.44B
FY201331 Dec 2013849.00M+52.78%11.88%7.15B
FY201231 Dec 2012555.70M+18.08%7.53%7.38B
FY201131 Dec 2011470.60M-34.72%6.27%7.51B
FY201031 Dec 2010720.90M-1.12%9.78%7.37B
FY200931 Dec 2009729.10M+25.38%9.78%7.46B
FY200831 Dec 2008581.50M+71.06%8.02%7.25B
FY200731 Dec 2007339.94M-42.03%5.07%6.70B
FY200631 Dec 2006586.42M+7.35%9.35%6.27B
FY200531 Dec 2005546.28M+9.43%9.93%5.50B
FY200431 Dec 2004499.20M+14.31%9.74%5.13B
FY200331 Dec 2003436.72M+35.56%9.22%4.74B
FY200231 Dec 2002322.15M+98.49%7.84%4.11B
FY200131 Dec 2001162.30M+59.04%4.47%3.63B
FY200031 Dec 2000102.05M—2.98%3.42B
FY199931 Dec 1999-3.40M-112.64%-0.15%2.21B
FY199831 Dec 199826.90M—1.84%1.46B
FY199731 Dec 1997-22.30M—-1.46%1.53B
FY199631 Dec 1996-625.96M—-38.73%1.62B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Quest Diagnostics's profit

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.